The G473D mutation impairs dimerization and catalysis in human sulfite oxidase.
Among the mutations identified in patients with isolated sulfite oxidase deficiency, the G473D variant is of particular interest since sedimentation analysis reveals that this variant is a monomer, and the importance of the wild-type dimeric state of mammalian sulfite oxidase is not yet well understood. Analysis of recombinant G473D sulfite oxidase indicated that it is severely impaired both in the ability to bind sulfite and in catalysis, with a second-order rate constant 5 orders of magnitude lower than that of the wild type. To elucidate the specific reasons for the severe effects seen in the G473D variant, several other variants were created, including G473A, G473W, and the double mutant R212A/G473D. Despite the inability to form a stable dimer, the G473W variant had 5-fold higher activity than G473D and nearly wild-type activity at pH 7.0 when ferricyanide was the electron acceptor. In contrast, the R212A/G473D variant demonstrated some ability to oligomerize but had undetectable activity. The G473A variant retained the ability to dimerize and had steady-state activity that was comparable to that of the wild type. Furthermore, stopped-flow analysis of the reductive half-reaction of this variant yielded a rate constant nearly 3 times higher than that of the wild type. Examination of the secondary structures of the variants by CD spectroscopy indicated significant random-coil formation in G473D, G473W, and R212A/G473D. These results demonstrate that both the charge and the large size of an Asp residue in this position contribute to the severe effects seen in a patient with the G473D mutation, by causing partial misfolding and monomerization of sulfite oxidase and attenuating both substrate binding and catalytic efficiency during the reaction cycle.
Department of Biochemistry, Box 3711, Duke University Medical Center, Durham, North Carolina 27710, USA.
Heather L
HL
Wilson
Sara R
SR
Wilkinson
K V
KV
Rajagopalan
D000595:Amino Acid Sequence; D002384:Catalysis / Q000187:drug effects; D002942:Circular Dichroism; D019281:Dimerization; D005292:Ferricyanides / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D050862:Oxidoreductases Acting on Sulfur Group Donors / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism*; D020836:Protein Structure, Quaternary / Q000187:drug effects
D005292:Ferricyanides; C007931:hexacyanoferrate III; D050862:Oxidoreductases Acting on Sulfur Group Donors; C503599:SUOX protein, human